.beta.-catenin, tcf-4, and apc interact to prevent cancer
CA 2285701 C · Owner: The Johns Hopkins University · Inventors: Barker, Nick; Kinzler, Kenneth W.; Morin, Patrice J.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The APC tumor suppressor protein binds to .beta.-catenin a protein recently , shown to interact with Tcf/Lef transcription factors. Here the gene encoding , a Tcf family member that is expressed in colonic epithelium (hTcf-4) was cloned and characterized. hTcf-4 transactivates transcription only when associated with .beta.-catenin. Nuclei of APC-/- colon carcinoma cells were found to contain a stable .beta.-catenin-hTCF-4 complex that was constitutively active, as measured by transcription of a Tcf reporter gene. Reintroduction of APC removed .beta.-catenin from hTcf4 and abrogated the transcriptional transactivation. Constitutive transcription of TCF target genes, caused by loss of …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed March 20, 1998 and granted September 17, 2013. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended March 20, 2018.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by March 20, 2020.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.